Sean Fenske, Editor-in-Chief03.14.24
Spirair has named Benjamin Bishop as its new CEO. The company is in the early stage of developing a minimally invasive solution to enable mechanical correction of nasal septal deviation.
“Our team is partnering with leading ENT advisors and industry veterans to develop minimally invasive solutions that provide strong outcomes and a better experience for their patients,” said Bishop. “I’m proud to join this team of innovators who are working to add treatment options to physicians’ toolkits to help them continue supporting their patients.”
Bishop brings two decades of experience in commercial leadership roles across medical, surgical, and aesthetic industries. He served in positions at Revelle Aesthetics, Revance Therapeutics, Access Closure, Arrinex, and ClariFix.
Spirair originated in the Stanford Biodesign innovation Fellowship program, which provides innovators with a repeatable process to identify health needs, invent a solution to address them, and incorporate the product into care protocols. The firm was founded by James Kintzing, Ph.D., and Brandon McCutcheon, M.D., who were involved in the program.
“As an alumna of the Stanford Biodesign Innovation Fellowship myself, I’ve seen firsthand how this program successfully supports groundbreaking ideas in healthcare technology—and Spirair is a shining example of this innovation,” said Kate Garrett, managing partner at Sonder Capital, assistant director of the Stanford Biodesign Innovation Fellowship and chair of Spirair’s board of directors. “Benjamin Bishop has an outstanding track record as a commercial leader and I’m thrilled to welcome him to Spirair as its chief executive officer as we begin this exciting next stage of growth.”
“Our team is partnering with leading ENT advisors and industry veterans to develop minimally invasive solutions that provide strong outcomes and a better experience for their patients,” said Bishop. “I’m proud to join this team of innovators who are working to add treatment options to physicians’ toolkits to help them continue supporting their patients.”
Bishop brings two decades of experience in commercial leadership roles across medical, surgical, and aesthetic industries. He served in positions at Revelle Aesthetics, Revance Therapeutics, Access Closure, Arrinex, and ClariFix.
Spirair originated in the Stanford Biodesign innovation Fellowship program, which provides innovators with a repeatable process to identify health needs, invent a solution to address them, and incorporate the product into care protocols. The firm was founded by James Kintzing, Ph.D., and Brandon McCutcheon, M.D., who were involved in the program.
“As an alumna of the Stanford Biodesign Innovation Fellowship myself, I’ve seen firsthand how this program successfully supports groundbreaking ideas in healthcare technology—and Spirair is a shining example of this innovation,” said Kate Garrett, managing partner at Sonder Capital, assistant director of the Stanford Biodesign Innovation Fellowship and chair of Spirair’s board of directors. “Benjamin Bishop has an outstanding track record as a commercial leader and I’m thrilled to welcome him to Spirair as its chief executive officer as we begin this exciting next stage of growth.”